
1. j oncol pract. 2011 may;7(3):141-7. doi: 10.1200/jop.2010.000133.

current hepatitis b screening practices clinical experience reactivation
in patients undergoing chemotherapy solid tumors: nationwide survey of
medical oncologists.

day fl(1), link e, thursky k, rischin d.

author information: 
(1)department medical oncology, centre biostatistics clinical trials, 
and department infectious diseases, peter maccallum cancer centre; university 
of melbourne, melbourne, victoria, australia.

purpose: universal screening chronic hepatitis b virus (hbv) before
chemotherapy recommended centers disease control. sought
to determine practice australian oncologists regard hbv screening 
in patients solid tumors (sts) clinical experience hbv
reactivation (hbvr).
methods: survey sent consultant members medical oncology
group australia. one hundred eighty-eight responses (63% response rate) were
received. also reviewed incidence hbv patients sts screened 
the peter maccallum cancer centre (melbourne, australia).
results: fifty-three percent medical oncologists screen hbv, 19% 
screen patients. common reasons given performing screening 
anecdotal experience hbvr (46%) perceived sufficient evidence for
screening patient subgroups (42%). sixty-five percent who
screened subgroups, usually selecting patients basis of
ethnicity (82%). oncologists screen commonly cited inadequate
evidence benefit screening (72%). twenty-two percent oncologists 
witnessed one hbvr events, representing one event per 45 years of
respondents' practice. hbvr events reported (n = 54) consisted asymptomatic
liver test abnormalities (44%), symptomatic hepatitis (28%), decompensated
liver failure (19%), death (7%). 206 patients sts screened hbv,
1.0% (n = 2) hbv surface antigen positive, 14.9% hepatitis b core
antibody positive.
conclusion: majority australian medical oncologists adopted
universal hbv screening chemotherapy. evidence benefit 
cost effectiveness universal screening patients sts required
to alter practice.

doi: 10.1200/jop.2010.000133 
pmcid: pmc3092651
pmid: 21886492 

